Researchers used a cross-vaccination strategy in the trial, which involved 33 healthy adult volunteers between the ages of 21 and 45.
C. difficile vaccine protected against C. difficile first-time infections and relapsing infections in animal models by eliciting a strong immune response, facilitating the removal of pre-existing C. diff bacteria from the gut
Despite being influenced by prior vaccinations, the new vaccine produces widely neutralizing antibodies in response.
Pfizer, Team, Public domain, via Wikimedia Commons FDA approves Pfizer’s new pneumococcal vaccines for children and infants on 27th April. The vaccine called Prevenar 20 [Read More…]
